Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 1:2022:21-0201.
doi: 10.1530/EDM-21-0201. Online ahead of print.

Thyroid dermopathy responds to teprotumumab therapy

Affiliations

Thyroid dermopathy responds to teprotumumab therapy

Ricaurte Crespo-Trevino et al. Endocrinol Diabetes Metab Case Rep. .

Abstract

Summary: Thyroid dermopathy is an uncommon manifestation of thyroid disease that impairs the quality of life in certain cases. Currently, the available treatments offer limited results and a chance of recurrence. Teprotumumab, a novel medication that results in the regression of thyroid ophthalmopathy, may have similar effects on dermopathy. We describe four patients treated with teprotumumab for their thyroid ophthalmopathy who concomitantly had dermatopathy upon initiation of their infusions. Patients improved after two to three infusions and three out of the four patients have not suffered a recurrence.Teprotumumab is a monoclonal antibody (MAB) that attenuates an inflammatory response, resulting in decreased edema and tissue expansion. Given the similarities of their pathophysiology, we believe that the resolution of thyroid dermatopathy and regression of thyroid eye disease occurs via the same mechanism. We encourage further investigation utilizing teprotumumab for patients whose dermopathy is associated with impaired quality of life.

Learning points: Thyroid dermopathy (TD), an uncommon manifestation of thyroid disease, may occasionally impair function and quality of life. There are only a few treatments for TD, with limited results and high rates of recurrence. Teprotumumab is a Food and Drug Administration-approved medication used for thyroid eye disease (TED). Our patients treated with teprotumumab for TED showed improvement of TD, which demonstrates its potential use for this condition.

PubMed Disclaimer

Figures

Figure 1
Figure 1
May 2018 after the second dose of teprotumumab treatment. Note the nodular growth above the right. Overall lower leg and ankle swelling and discoloration (right greater than left). Both halluxes thickened (left greater than right) with nodularity on the left.
Figure 2
Figure 2
July 2018 after teprotumumab. Note that the nodular growth on the right leg has flattened significantly and overall swelling of both legs and ankles have decreased. Marked improvement in both halluxes, especially nodularity on left.

References

    1. Schwartz KM, Fatourechi V, Ahmed DDF, Pond GR. Dermopathy of Graves’ disease (pretibial myxedema): long-term outcome. Journal of Clinical Endocrinology and Metabolism 200287438–446. (10.1210/jcem.87.2.8220) - DOI - PubMed
    1. Fatourechi V.Pretibial myxedema: pathophysiology and treatment options. American Journal of Clinical Dermatology 20056295–309. (10.2165/00128071-200506050-00003) - DOI - PubMed
    1. Krieger CC, Neumann S, Place RF, Marcus-Samuels B, Gershengorn MC. Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves’ disease immunoglobins. Journal of Clinical Endocrinology and Metabolism 20151001071–1077. (10.1210/jc.2014-3566) - DOI - PMC - PubMed
    1. Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marinò Met al.Teprotumumab for the treatment of active thyroid eye disease. New England Journal of Medicine 2020382341–352. (10.1056/NEJMoa1910434) - DOI - PubMed
    1. Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RAet al.Teprotumumab for thyroid-associated ophthalmopathy. New England Journal of Medicine 20173761748–1761. (10.1056/NEJMoa1614949) - DOI - PMC - PubMed

LinkOut - more resources